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Abstract
Background: Prion disease transmission and pathogenesis are linked to misfolded, typically protease resistant
(PrP
res) conformers of the normal cellular prion protein (PrP
C), with the former posited to be the principal
constituent of the infectious ‘prion’. Unexplained discrepancies observed between detectable PrP
res and infectivity
levels exemplify the complexity in deciphering the exact biophysical nature of prions and those host cell factors, if
any, which contribute to transmission efficiency. In order to improve our understanding of these important issues,
this study utilized a bioassay validated cell culture model of prion infection to investigate discordance between
PrP
res levels and infectivity titres at a subcellular resolution.
Findings: Subcellular fractions enriched in lipid rafts or endoplasmic reticulum/mitochondrial marker proteins were
equally highly efficient at prion transmission, despite lipid raft fractions containing up to eight times the levels of
detectable PrP
res. Brain homogenate infectivity was not differentially enhanced by subcellular fraction-specific co-
factors, and proteinase K pre-treatment of selected fractions modestly, but equally reduced infectivity. Only lipid
raft associated infectivity was enhanced by sonication.
Conclusions: This study authenticates a subcellular disparity in PrP
res and infectivity levels, and eliminates
simultaneous divergence of prion strains as the explanation for this phenomenon. On balance, the results align
best with the concept that transmission efficiency is influenced more by intrinsic characteristics of the infectious
prion, rather than cellular microenvironment conditions or absolute PrP
res levels.
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Background
Prion diseases constitute a group of unique neurodegen-
erative disorders, which naturally afflict a number of
mammalian species including humans. Although our
understanding remains incomplete, considerable evi-
dence supports the “protein-only” hypothesis, which
purports that the agent (“prion”) responsible for both
transmission and consequent pathogenesis is predomi-
nantly composed of misfolded conformers of the normal
cellular prion protein PrP
C [1]. Additional discriminat-
ing features of the aberrant prion protein include
increased b-sheet content [2,3], reduced solubility and
increased tendency to aggregate, and typically heigh-
tened protease resistance [4-6]. Due to the characteristic
protease resistant core, limited proteolysis with protei-
nase K (PK) truncates the N-terminus of the misfolded
protein, producing PrP
res, whilst PrP
C is completely
degraded, allowing a convenient biochemical differentia-
tion of these two prion protein isoforms.
An intriguing but somewhat perplexing aspect of prion
biology is the several instances in transmission studies,
encompassing many prion strains, where infectivity titres
and PrP
res levels (as detected by biochemical assessment
of inocula) do not faithfully correlate. Illustrating this are
pre-clinical prion infections after low dose transmissions
[7], BSE infectivity in tongue and nasal mucosa [8] and
slowly sedimenting high titres of infectivity separated
from PrP
res in ‘fast’ prion strains [9]. Further examples
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any medium, provided the original work is properly cited.have occurred during cross species transmissions includ-
ing intracerebral inoculation of hamster prions to mice
[10], primary passage of bovine prions to rodents [11,12],
scrapie prions peripherally introduced into mice [13] and
transmission of three distinct prion strains (human, ham-
ster scrapie, murine scrapie) into transgenic mice expres-
sing the murine equivalent of a human prion protein
gene mutation [14]. In addition, PrP
res generated through
protein misfolding cyclic amplification (PMCA) evinces a
longer incubation period (indicative of a lower titre)
despite western blot detection levels equivalent to those
observed in the original seeding inoculum [15]. This
PMCA study suggests that a component within the origi-
nal inoculum, which perhaps does not propagate or
amplify as well as PrP
res, may contribute to the more effi-
cient transmission. Although PrP
res is inextricably linked
to prion infectivity, these numerous examples clearly
illustrate the poorly understood complexities of this
relationship.
The precise cellular location of PrP
C misfolding and
conversion also remains speculative (reviewed in [16]), as
does the contribution of cellular co-factors to conversion
efficiency, although the participation of a species-specific
protein [17-19], or negatively charged macromolecules
such as nucleic acids [20-24] and glycosaminoglycans
[25-29] has been posited. In contrast, evidence exists cor-
relating the efficiency of prion propagation and transmis-
sion with the size of prion multimers serving as templates
for conversion [30,31]. Acknowledging the aforementioned
uncertainties, the current study investigated whether such
observed disparities between infectivity titres and PrP
res
levels could be resolved to a subcellular level and thereby
provide a useful model for insights into the molecular
basis of this observation. To address this aim, we utilized
fractionation of MoRK13 cells infected with M1000 prions
to explore the contributions of subcellular co-factors
and cognate prion protein species to the efficiency of
transmission.
Results
Prion protein conformers reside predominantly in lipid
rafts in MoRK13 and MoRK13-inf cells
Characterisation of the MoRK13-M1000 prion infection
model (MoRK13-inf) determined that per detectable
‘PrP
res unit’, MoRK13-inf cell lysate was approximately
90 times more efficient than crude M1000 brain homoge-
nate at prion transmission to recipient MoRK13 (Addi-
tional file 1: Figure S1). This finding, perhaps an example
of strain adaptation into a rabbit cell line, highlighted a
discrepancy between PrP
res and infectivity levels, and indi-
cated that MoRK13-inf cells may be an appropriate model
to study this phenomenon. PrP isoforms have been shown
to localise to various subcellular environments, including
those of the secretory and endocytic pathways, and at the
cell surface [32-34]. Figure 1 shows the localisation of
organelle markers Bcl-2 (mitochondria; MT), Bip (endo-
plasmic reticulum; ER), and EEA1 (early endosome; EE) in
the MoRK13 cells. As expected, the lipid raft marker Flo-
tillin 1 was enriched within fractions at the buoyant end of
the gradient, consistent with the high cholesterol:protein
ratio resulting in a significantly lower density of lipid rafts
compared to other solubilised membrane proteins [35].
This was confirmed by dot blot analysis of the lipid raft
marker GM1, detected by the cholera toxin subunit B
(CTB). Figure 1 also indicates that the subcellular localisa-
tion of PrP
C in MoRK13, and total PrP (PrP
C and PrP
res,
indistinguishable from each other under the conditions of
these western blots) in MoRK13-inf is predominantly in
the buoyant, lipid raft fractions. There were no substantial
differences in organelle or membrane markers or PrP loca-
lisation when comparing the MoRK13 and MoRK13-inf
cells, and also comparing vector-only transfected RK13
(vecRK13), GT1-7H and GT1-7H-inf cells (Additional file
2: Figure S2); therefore over-expression of PrP
C,p r i o n
infection and cell line origin (neuronal/non-neuronal/mur-
ine/rabbit) do not appear to alter localisations, or create
artefacts in this system of subcellular fractionation. Pre-
vious reports indicate PrP
res is also localised in lipid rafts
[36]. Figure 2A shows the localisation of MoRK13-inf
PrP
res to be principally in lipid raft fractions, with a similar
distribution to total PrP (Figure 1) as determined by both
western blot and dot blot. Quantification of relative PrP
res
levels (Figure 2B) highlights that the lipid raft enriched
fractions contain up to eight times the detectable PrP
res
levels than the ER/MT marker enriched fractions (eg com-
pare fractions #3 and #8). By way of comparison to the
original prion strain, Nycodenz gradient distribution of
PrP isoforms and marker proteins from M1000 brain,
homogenised in a comparative manner, was also similar to
that observed in cell lysates (Additional file 3: Figure S3).
High levels of prion infectivity are present in lipid raft
and ER/MT marker enriched fractions of MoRK13-inf cells
In order to determine whether detectable subcellular
PrP
res levels correlate with infectivity, an in vitro cell
culture transmission study was carried out of equivalent
volumes of fractions obtained after density gradient flo-
tation assays of MoRK13-inf cell lysate using the highly
susceptible MoRK13 as recipient cells. Levels of PrP
res
produced by recipient cells after exposure to fractions
were quantified and used as a surrogate indicator of
relative infectivity titres contained within the subcellular
fractions. The representative cell blot and quantification
(Figure 3A, B) clearly show that infectivity was con-
tained within all fractions derived from MoRK13-inf
cells, albeit to varying degrees. The EE enriched frac-
tions (predominantly #9 and #10) contained consider-
ably less infectivity compared with the lipid raft
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Figure 1 MoRK13 and MoRK13-inf PrP localises predominantly to lipid raft fractions. Representative immunoblots of subcellular fractions
(1-10) obtained from MoRK13 and MoRK13-inf. Equivalent volumes of each fraction were resolved on gradient gels. Proteins were transferred to
PVDF, which was sectioned based on the predicted molecular weight of the protein of interest, with each PVDF strip probed with the relevant
antibody. CTB dot blot - 3 μl of fraction was dried onto nitrocellulose membrane, and blotted as described in the methods. LR = lipid raft; ER =
endoplasmic reticulum; MT = mitochondria; EE = early endosome; CTB = cholera toxin subunit B (LR marker); Flot1 = Flotillin 1 (LR marker); Bcl-2
= anti-apoptotic MT marker protein; Bip = ER lumen chaperone protein; EEA1 = EE antigen 1.
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Page 3 of 17enriched fractions (predominantly #3 and #4), and the
ER and MT marker enriched fractions (predominantly
#7 and #8), although the comparison of fraction #7 and
fraction #9 did not reach significance. Interestingly,
there was no significant difference in the amount of
infectivity contained within the lipid raft enriched frac-
tions (#3 and #4), and the ER and MT marker enriched
fractions (#7 and #8). As shown in Figure 3A, fractions
were also diluted in a 1/2 log series, to ensure there was
no limiting sensitivity of the in vitro assay truncating the
upper end of the dynamic range. Importantly, neat frac-
tions that elicited the highest production of PrP
res by reci-
pient MoRK13 cells (for example fractions #4 and #8),
were infectious to the same dilutions (1:100), thereby vali-
dating the use of PrP
res produced by recipient cells as a
measure of relative infectivity contained within fractions.
ER and MT marker enriched fractions show disparity
between PrP
res levels and infectivity titres in vitro and
in vivo
Correlation of the percentage of PrP
res present in each
fraction with the level of in vitro infectivity produced by
each fraction (Figure 4A) revealed a discrepancy in the
ER/MT enriched fractions. The relative levels of PrP
res
present in the lipid raft enriched fractions (#3 & #4) and
the early endosome enriched fractions (#9 and #10) cor-
respond with the relative levels of PrP
res produced by the
recipient MoRK13 cells. In contrast, the ER/MT enriched
fractions (#7 and #8) that display low detectable PrP
res
levels, contained high infectivity levels similar to the lipid
raft enriched fractions, with the discrepancy at fraction
#8 highly significant (p < 0.001; two way ANOVA).
Therefore, there was a reproducible and significant
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Figure 2 PrP
res is enriched in lipid raft fractions of MoRK13-inf cells. (A) Equivalent volumes of PK treated MoRK13-inf fractions resolved on
10-20% Tris-glycine SDS PAGE and immunoblotted (top panel), and representative fraction PrP
res dot blot (bottom panel). (B) Quantification of
PrP
res from dot blots of six separate cellular fractionations. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial (MT)
and early endosome (EE) marker proteins are highlighted. Comparison of relative PrP
res levels by one way ANOVA; *** p < 0.001, ns = not
significant.
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Page 4 of 17divergence between PrP
res and infectivity levels within
ER/MT marker enriched fractions.
To confirm genuine prion infectivity, selected fractions
were bioassayed in Tga20 PrP
C over-expressing mice. The
fractions were chosen to provide a range of PrP
res and
infectivity level combinations; ie high PrP
res and infectivity
levels (fraction #4), low PrP
res and infectivity levels (frac-
tion #10), and low PrP
res but high infectivity levels (frac-
tion #8). Controls included inoculating mice with whole
cell lysate from naive MoRK13 and MoRK13-inf cells, as
well as M1000 brain homogenate, in order to make com-
parisons with the original prion strain. Figure 4B depicts
the incubation periods for the selected fractions and con-
trol mice. Mice exposed to uninfected MoRK13 cell lysate
were symptom free at 245 days post-inoculation. Mice
inoculated with 0.01% M1000 brain homogenate had a sig-
nificantly shorter incubation period than mice inoculated
with MoRK13-inf whole cell lysate. Importantly, concor-
dant with the in vitro cell culture transmissions, mice
inoculated with fractions #4 and #8 had indistinguishable
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Figure 3 All MoRK13-inf fractions contain infectivity. (A) Representative cell blot showing PrP
res levels produced by recipient MoRK13 cells at
passage 4 (P4) post-exposure to equal volumes of each fraction at the ‘neat’ dilution (N) or further serially diluted (1/10-1/1000). (B)
Quantification of infectivity from three independent MoRK13-inf fractionations (n = 3); fractions enriched in lipid raft (LR), endoplasmic reticulum
(ER), mitochondrial (MT) and early endosome (EE) marker proteins are highlighted. Statistical analysis by one way ANOVA; only the statistical
findings for relevant comparisons are indicated: *** p < 0.001, ** p < 0.001, * p < 0.05, ns = not significant.
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Figure 4 Disparity in subcellular fraction PrP
res levels and relative infectivity in vitro and in vivo. (A) Relative amounts of PrP
res contained
within MoRK13-inf fractions (dot blot - top panel, also Figure 2; red line) plotted against relative infectivity of each fraction (PrP
res produced by
recipient MoRK13 - bottom panel, also Figure 3; blue line). There is a highly significant separation of relative PrP
res and infectivity levels observed
in fraction #8; statistical analysis was by two way ANOVA; *** p < 0.001. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER),
mitochondrial (MT) and early endosome (EE) marker proteins are highlighted. (B) Mean survival (horizontal bar) of Tga20 mice inoculated with
0.01% (w/v in PBS) M1000 brain homogenate, whole cell lysate from MoRK13 and MoRK13-inf cells, and selected subcellular fractions from
MoRK13-inf. Each data point represents the number of days post-inoculation (PI) that a terminally ill mouse was sacrificed, with the exception of
Tga20 mice inoculated with MoRK13 cell lysate (#) which were symptom free when culled at 245 days PI. Mice inoculated with 0.01% (w/v)
M1000 brain homogenate had a significantly shorter incubation period than those exposed to all other inocula. Mice inoculated with fraction
#10 had a significantly longer incubation period compared to mice exposed to all other infectious inocula. Statistical analysis was by one way
ANOVA; *** p < 0.001.
Lewis et al. Molecular Neurodegeneration 2012, 7:18
http://www.molecularneurodegeneration.com/content/7/1/18
Page 6 of 17incubation periods, despite the significantly different PrP
res
levels contained within these fractions. Mice inoculated
with fraction #10 had significantly longer incubation peri-
ods than mice infected with the other two fractions, again
concordant with the relative infectivity levels determined
by the cell culture transmissions. For illustrative purposes,
this 35 day extension in incubation period approximates a
3 log reduction of infectious titre when modelled on a
time interval assay developed in Tga20 mice inoculated
with M1000 brain homogenate derived prions (Additional
file 4: Figure S4). In summary, the in vivo findings faith-
fully recapitulate and validate the MoRK13 in vitro model.
Infectious prions from different subcellular fractions do
not induce unique disease in vivo
Neuropathologically, prion diseases are characterised by
the presence of neuronal loss, spongiform change, prolif-
eration of astrocytes and extracellular PrP deposits [37].
Further, for different prion strains the topographical dis-
tribution of neuropathological changes is distinctive,
creating characteristic lesion profiles [38,39]. All diseased
mice displayed symptoms typical of M1000 prion infec-
tion and brains were harvested to assess neuropathologi-
cal changes. As expected, control mice inoculated with
MoRK13 whole cell lysate showed no neuropathological
abnormalities (Additional file 5: Figure S5). Figure 5 dis-
plays the quantification of the neuropathological features
mentioned above within different brain regions, clearly
indicating that each inoculum produced very similar
lesion profiles (for representative photomicrographs of
the histological and immunohistochemical findings see
Additional file 5: Figure S5). This distribution pattern of
the pathological features, with predominant involvement
of the thalamus, midbrain and pons, and minimal invol-
vement of the cerebellum is consistent with previous
observations of the M1000 strain [40,41]. The only signif-
icant difference detected in lesion profiles was between
MoRK13-inf whole cell lysate and fraction #10 inocula,
with the former having significantly more reactive astro-
cytes in the occipital cortical region. The explanation for
this is uncertain, but may suggest an additive effect of the
individual fractions, which contribute to the whole-cell
lysate profile. Different prion strains often have distinc-
tive PrP
res glycoform ratios and mobilities on western
blot analysis [42-46]. To further evaluate the possibility
of different MoRK13-inf subcellular fractions associating
with distinct prion strains, the brain PrP
res profiles from
Tga20 mice inoculated with selected fractions were
examined by western blot. Similar to the lesion profiling,
there were no significant differences in PrP
res patterns
when comparing MoRK13-inf whole cell lysate with each
of the selected fractions, in keeping with them all being
the same prion strain (Additional file 6: Figure S6).
The efficiency of M1000 prion transmission is not
enhanced by exogenous fraction specific co-factors in
vitro or in vivo
In order to explore whether subcellular fraction specific
co-factors might contribute to the observed transmission
efficiency spectrum, M1000 brain homogenate was
spiked into fractions derived from uninfected MoRK13
or vecRK13 cells, prior to use as inocula in vitro.F i g u r e
6A shows that even at the lowest dilutions of M1000 in
MoRK13 fractions, PrP
res was produced by recipient
MoRK13 cells. However, quantification (Figure 6B)
shows there were no significant differences in amounts of
PrP
res produced when comparing the various MoRK13
subcellular fraction diluents. Notably, there was a general
trend for MoRK13 subcellular fractions to enhance
M1000 transmission efficiency to MoRK13 cells com-
pared to lysis buffer alone. A similar result was observed
using fractions obtained from vecRK13 cells (Additional
file 7: Figure S7), suggesting this trend is not PrP
C speci-
fic or dependent.
To further evaluate the possible contribution of cellular
co-factors on the efficiency of prion infection, M1000
brain homogenate was diluted in PBS or selected subcel-
lular fractions from uninfected MoRK13 cells (fractions
#4, #8 and #10), and bioassayed in Tga20 indicator mice.
M1000 was also diluted in ‘empty’ Nycodenz fractions
(#4, #8 and #10), in order to control for any affect the
Nycodenz gradient material itself may have on incubation
period or the neuropathology. Neither the exogenous cel-
lular co-factors in the selected fractions, nor Nycodenz
alone, had any significant affect on the incubation time
(Figure 6C) or overtly affected the neuropathology (Add-
tional file 8: Figure S8) of M1000 in Tga20 mice.
Discrepancies between PrP
res and transmission efficiency
are not due to protease-sensitive prions, and only in lipid
raft enriched fractions is infectivity enhanced by
sonication
There is experimental evidence that some disease asso-
ciated [47-50], and synthetic [51] prions, may be protease
sensitive. To test whether the infectious prions within the
MoRK13-inf fractions may differentially contain significant
amounts of protease sensitive species, selected fractions
were digested mildly with PK prior to using them as a
source of infectivity. There were no significant differences
in PrP
res levels produced by MoRK13 infected with PK
digested fractions #4, #8 or #10 compared to cells infected
with the untreated fraction counterpart (Figure 7A, B).
However there was a modest general trend towards
reduced PrP
res production by recipient cells after PK treat-
ment of each fraction inoculum.
Evidence suggests misfolded prion protein aggregate
size correlates with efficiency of conversion or prion
Lewis et al. Molecular Neurodegeneration 2012, 7:18
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Figure 5 Lesion profiles from Tga20 mice intracerebrally inoculated with M1000, MoRK13 and MoRK13-inf whole cell lysates and
selected MoRK13-inf fractions. Lesion profiles generated by quantification of the degree of vacuolation, reactive astrocytosis and PrP plaques
in each brain region (HI - hippocampus, TH - thalamus, OP - occipital pole, CE - cerebellum, MB - midbrain, PO - pons) in Tga20 mice inoculated
as indicated. n = 3 or 4 for all brain regions except in MoRK13-inf whole lysate HI H&E and 0.01% M1000 HI PrP plaque deposition, where n = 2.
Statistical analysis comparing lesion profiles was by two way ANOVA. The only significant difference was comparing MoRK13-inf and Fraction #10
in OP region (*p < 0.05).
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Figure 6 Exogenous cellular co-factors do not modify the efficiency of M1000 infection in vitro or in vivo. (A) Representative cell blot showing
PrP
res levels produced by recipient MoRK13 cells exposed to M1000 brain homogenate diluted to three different final concentrations (as indicated)
with either 1:4 lysis buffer (LB):medium or 1:4 MoRK13 fraction:medium mix. (B) Quantification of PrP
res produced by MoRK13 cells exposed to M1000
brain homogenate diluted in subcellular fraction relative to the equivalent % M1000 brain homogenate diluted in lysis buffer; data is from M1000
spiked into three independent fractionations of MoRK13. For quantification purposes, the three different % M1000 spikes into the same MoRK13
fractionated lysate were considered a triplicate of the same experiment. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial
(MT) and early endosome (EE) marker proteins are highlighted. Analysis of relative levels of PrP
res produced after infection was by one-way ANOVA
with Tukey’s multiple comparison test; no significant differences found comparing subcellular fractions. (C) Survival of Tga20 mice inoculated with
M1000 brain homogenate diluted to 0.01% with either PBS, selected fractions from an empty Nycodenz gradient, or selected subcellular fractions from
MoRK13 cells. Each data point represents the number of days post-inoculation (PI) which mice were sacrificed because of terminal prion disease.
Statistical analysis was by one way ANOVA, with no significant differences in survival seen between any inocula.
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Figure 7 Sonication but not PK treatment alters efficiency of in vitro infection with fraction #4 only. (A) Representative cell blot (left
panel) of PrP
res produced by MoRK13 cells exposed to selected MoRK13-inf fractions which were PK digested (PK) or left untreated (UN) and
western blot (right panel) of MoRK13-inf inocula before and after PK treatment. (B) Quantification of cell blot PrP
res levels (n = 3 independent
experiments), with PrP
res produced after infection with PK treated inocula expressed relative to untreated MoRK13-inf fraction inocula. (C)
Representative cell blot (left panel) of PrP
res produced by MoRK13 cells exposed to selected MoRK13-inf fractions which were sonicated (SON) or
left untreated (UN) and western blot (right panel) of MoRK13-inf fraction inocula before and after sonication. (D) Quantification of cell blot PrP
res
levels expressed relative to untreated MoRK13-inf fraction inocula (n = 3 independent experiments). Note, levels of total PrP in fractions #8 and
#10 are at or below the limits of detection by standard immunoblotting. Comparison of relative PrP
res levels by one way ANOVA and Dunnett’s
post-test for specific comparisons to a control (ie untreated fraction) found no significant differences in any PK treated inocula, and only
sonicated MoRK13-inf fraction #4 was significantly different compared to its untreated control, *p < 0.05.
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assays such as PMCA may be most efficient when incor-
porating sonication steps [52,53]. To assess this possibi-
lity, selected fractions (#4, #8 and #10) were subjected
to sonication (equivalent to one ‘round’ of PMCA) prior
to using them as a source of infectivity in the MoRK13
cell culture model. As demonstrated by the representa-
tive cell blot in Figure 7C, quantified in Figure 7D, only
subcellular fraction #4 had significantly increased levels
of infectivity compared to its untreated fraction.
Discussion
The protein-only hypothesis states that misfolded confor-
mers of the normal cellular prion protein are the principal
component of the agent responsible for transmitting prion
disease [1]. However, previously observed examples of
high infectivity titres associated with very low or undetect-
able PrP
res, the commonly utilized surrogate prion marker,
suggest a poorly understood spectrum of infectious prions.
Assessing the subcellular environment of the most infec-
tious prions may provide information about optimal pH or
metal content conditions, implicate membrane domains,
or subcellular co-factors involved in localisation of highly
efficient prions. Investigation of the subcellular distribu-
tion of prion infectivity and corresponding PrP
res levels
has been previously reported, albeit to a limited extent.
However, absent in prior studies were attempts to explore
what determines the intracellular topographical diversity
of prions or the molecular basis of any observed discre-
pancies in PrP
res and infectivity levels.
The present study clearly indicates that not all prion
infectivity is associated with lipid rafts, although the sig-
nificance of the lipid raft microenvironment in PrP
C mis-
folding and prion conversion is yet to be resolved, with
experimental evidence both for and against lipid raft
localisation as an optimal site (reviewed in [16]). In com-
plete agreement with the protein-only hypothesis, lipid
raft and EE marker associated infectivity and PrP
res were
shown to correlate in the MoRK13-inf model. In contrast
however, ER/MT marker enriched fractions contained
much greater infectivity when reported to relative PrP
res
content. That lipid raft and ER/MT enriched fractions
contain the same infectivity levels indicates some biologi-
cal redundancy or relative inefficiency of the lipid raft
localised prions, and/or higher efficiency of ER/MT loca-
lised prions, prompting further investigation.
Cell-free conversion studies have shown there is a role
for cellular co-factors, such as nucleic acid or other poly-
anionic molecules, in the efficiency of prion conversion
and propagation [21-23,29,54]. Perhaps militating against
a prominent role of specific co-factors contributing to
the transmission efficiency of the MoRK13-inf subcellular
fractions, infectivity of brain derived M1000 prions was
not significantly differentially enhanced by dilution across
various subcellular fractions. However, an explanation for
this result is that the transmissible prions within M1000
brain homogenate were already largely in an optimal
state, pre-formed and associated with the necessary co-
factors required for infection. Therefore additional exo-
genous co-factors supplied via the MoRK13 or vecRK13
subcellular fractions were somewhat superfluous. Alter-
natively, the fractionation procedure itself may have inac-
tivated any critical co-factors, such that they were not
able to significantly enhance the infectivity of M1000
brain homogenate. In fact, there was a clear trend for
increased PrP
res propagation by recipient cells after infec-
tion with M1000 diluted in subcellular fractions com-
pared to the lysis buffer only control, independent of
whether the fractions contained PrP
C. This may indicate
that incompletely defined but relatively ubiquitous ‘cellu-
lar co-factors’ contribute to the efficiency of in vitro
prion transmission, which would be consistent with pre-
vious studies.
Numerous prion strains exist, evident in both naturally
occurring human [55,56] and animal [38,57-60] prion dis-
ease, as well as those adapted to laboratory based animal
models. One hypothesis for what determines different
strains is the tertiary structure of the prion conformer,
possibly affected by metals, co-factors or binding partners
[61]. It is also believed that prions may adopt various
stable tertiary conformations, and there is evidence of
simultaneous propagation of more than one prion strain
within the brain [55,62,63]. Furthermore, super-infection
experiments indicate that the more infectious strain will
predominate and determine disease expression [64-66].
Prion strains can be classified by their distinctive neuro-
pathological lesion profiles, incubation periods, PrP
res gly-
cosylation patterns and electrophoretic mobilities
[39,42,43,46]. As RK13 cells are capable of supporting and
maintaining propagation of many prion strains [67], and
each fraction represented different subcellular localisations
and potential binding partners, we explored the possibility
that MoRK13-inf fractions contained structurally distinct
prions of variable transmission efficiency. However histo-
logical and western blot analyses failed to detect any evi-
dence of a subcellular divergence of prion strains, strongly
militating against this as the explanation for the apparent
increased relative infectivity in the ER/MT marker
enriched fractions.
Previous experiments have shown that PrP
res aggregate
size affects the efficiency of conversion and prion infec-
tion, perhaps through effects on optimising the available
templating surface [30,31], with oligomers of five or fewer
PrP
res molecules and larger fibrillar aggregates of PrP
res far
less efficient than non-fibrillar particles of 14-28 molecules
[30]. There is also experimental evidence that a proportion
of disease associated prions are protease sensitive [47-49],
which may form low molecular weight aggregates [47,49].
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portion of prion infectivity within MoRK13-inf fractions is
protease sensitive, and is unlikely to account for the dis-
connect observed between PrP
res levels and infectivity in
the ER/MT and lipid raft enriched fractions. Rather, the
sonication results are in keeping with a greater proportion
of multimeric assemblies, fibrils or aggregated species of
prions existing in the lipid raft compared to ER/MT mar-
ker enriched fractions, with sonication increasing the
number of replication-competent prion oligomeric strand
ends which are then more efficient at transmission and
inducing prion propagation. Recent publications provide
credence to this hypothesis [68,69], with direct visualisa-
tion of the fragmentation of recombinant PrP after sonica-
tion. However, the current study does not exclude any
positive effect that sonication may have had on other cel-
lular components contained within the fraction mileu or
interactions between the prion protein and other mole-
cules. In fact another recent publication [70] found that
sonication also fragments purified liver RNA, to a size that
has previously been shown to stimulate prion conversion
in PMCA assays. However the RNA sonication produced
optimal (sized) RNA after approximately 8 cycles, whereas
our sonication experiment was equivalent to one cycle,
giving some support to the plausibility of our former
hypothesis. Ongoing studies, including the utilisation of
techniques such as the conformation dependent immu-
noassay (CDI) to measure prions in the fractions [71], and
sophisticated size fractionation techniques, will help clarify
the exact biophysical nature of the variably efficient prion
species in the lipid raft and ER/MT enriched fractions.
The association of prion infectivity with MT and ER has
been previously investigated with conflicting results. One
s t u d ys h o w e dt h a tp u r i f i e dm i t o c h o n d r i aa n dm i t o p l a s t
fractions from scrapie infected hamster brain contained
infectivity titres equivalent to those determined for crude
brain homogenate, yet mitoplast fractions were not asso-
ciated with detectable levels of PrP [72], in keeping with
the findings of the present study. These results, which sug-
gested an association of high levels of scrapie infectivity
with the inner mitochondrial membrane or mitochondrial
matrix, are broadly consistent with the characteristics of
MoRK13-inf ER/MT enriched fractions, which co-loca-
lised with the mitochondrial membrane marker Bcl-2 [73].
An integral and unique (to mitochondria) lipid component
of the inner mitochondrial membrane is cardiolipin, a
form of dimeric phosphatidylglycerol [74]. Interestingly,
utilizing serial PMCA, researchers have recently been able
to produce protease resistant, infectious prions from
recombinant PrP mixed with RNA and the synthetic phos-
phatidylglycerol, POPG (1-palmitoyl-2-oleoylphosphatidyl-
glycerol) [75]. The authors state that the POPG and RNA
additives to their PMCA may be mimicking factors which
facilitate the conversion process in vivo, which is entirely
consistent with the results presented here implicating
mitochondrial component enriched fractions as containing
highly efficient infectious prions.
Somewhat incongruent with these observations, a
much earlier study examined the infectivity of scrapie
within membrane fractions and found that brain derived
purified mitochondrial fractions were associated with
very little infectivity [76]. Nevertheless, similar to our
results, Millson and colleagues [76] did find both brain
and spleen derived subcellular fractions containing ele-
vated enzyme activities usually associated with the ER
and plasma membrane were associated with high scrapie
infectivity. Conversely, Alais and colleagues [77] found
fractions enriched in the ER marker Bip harboured no
infectivity, despite containing moderate levels of PrP
res.
This result, whilst presenting another example of discre-
pancy between PrP
res levels and infectivity, clearly con-
trasts with what was observed in the MoRK13-inf
fractions, perhaps reflecting the different methods and
prion strain-cell model employed.
Conclusions
Through the use of both in vitro and in vivo transmis-
sion studies, we have corroborated previously reported
discrepancies between absolute PrP
res levels and infectiv-
ity and provided insight into the basis of this phenom-
enon. Through subcellular separation of infectivity, our
data indicates that a substantial amount of infectivity is
contained outside of buoyant lipid raft fractions and
importantly showed that the most transmission efficient
prions per detectable PrP
res unit were associated with
either ER and/or MT membranes or proteins. We estab-
lished that the high transmission efficiency shown by
the ER/MT containing fractions was not due to the
simultaneous separation of a more potent prion strain.
As critical co-factor enrichment could not be completely
excluded, it remains to be determined whether cellular
microenvironments directly but variably contribute to
the transmission efficiency of resident prions, or only
passively serve as sequestration sites for the different
prion species. Overall the current study broadly aligns
with the notion that rather than absolute levels of PrP
res,
intrinsic prion properties may dictate or be dictated by
the ultimate subcellular localisation of infectious prions,
with transmission efficiency likely correlating best with
optimal prion oligomeric state for template directed
conversion. Importantly, through the development and
validation of a tractable model, further detailed explora-
tion of these fundamental aspects of prion biology,
including assessment of other cell line-prion strain com-
binations to determine the breadth of applicability of
our observations, can be undertaken.
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Cell culture
Rabbit kidney epithelial cells which have no detectable
endogenous PrP
C protein, were stably transfected to over-
express murine PrP
C (MoRK13) or the empty vector
(vecRK13) [78] and mouse hypothalamic GT1-7H cells
were maintained as described previously [79], in a humidi-
fied incubator at 37°C with 5% CO2.
Subcellular fractionation
A method of non-toxic/non-detergent cell lysis and sub-
cellular separation was necessary to allow subsequent use
of fractions for infecting recipient cells or mice. Also, due
to the possible involvement of lipid rafts in prion conver-
sion, a lysis method was chosen in order to maintain lipid
raft integrity and buoyancy [35], with minor modifications.
Briefly two confluent T175 cm
2 flasks (approximately
4 x10
7 cells) were washed twice with 20 mls ice cold lysis
buffer (20 mM Tris-Cl pH 7.8, 250 mM sucrose, 1 μM
CaCl2,1μMM g C l 2)a n dh a r v e s t e db ys c r a p i n gi n t oa
further 20 ml of lysis buffer and pelleting at 700 × g for
3 minutes. The cell pellet was re-suspended in 500 μlc o l d
lysis buffer. Cells were lysed on ice, by passing the cell sus-
pension through a 22 g needle exactly twenty times, and
the crude lysate was centrifuged at 1000 × g, 10 minutes
at 4°C. The post-nuclear supernatant was retained on ice
and the extraction repeated on the pellet. The lysate was
then assayed for total protein content by performing a
bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific,
Scoresby, VIC, AUS) as per the manufacturer’si n s t r u c -
tions, and adjusted with lysis buffer to 1.8 mg/ml. The
Nycodenz (HistoDenz™, Sigma-Aldrich, Castle Hill,
NSW, AUS) density gradient fractionation method was
adapted from a published protocol [80], to suit a Beckman
Optima Max-E Benchtop Ultracentrifuge and MLS-50
rotor. Nycodenz solutions were prepared in TNE (25 mM
Tris-Cl pH 7.5, 150 mM NaCl, 5 mM EDTA) and an 8-
35% linear step Nycodenz gradient was poured (400 μlo f
each of 8%, 12%, 15%, 18%, 20%, 22.5% and 25%) with 1.1
ml of a 35% Nycodenz cushion consisting of equal parts
ice cold 70% Nycodenz and cell lysate (1 mg total protein)
pipetted to the bottom of the gradient. In some cases, an
‘empty Nycodenz’ gradient was poured, whereby the 35%
Nycodenz/lysate cushion mixture was substituted for 35%
Nycodenz alone. Nycodenz gradients were centrifuged at
200,000 × g (average) for 342 minutes at 4°C. Following
centrifugation, 10 equal volume fractions of 390 μlw e r e
collected and stored at -80°C or kept on ice for immediate
use.
Prion strain and cell infections
The M1000 prion strain used in this study was derived
from a well characterised stock of pooled mouse brain
homogenate [81]. Recipient MoRK13 or GT1-7H cells
were infected using an overlay technique as described
previously [79]. For comparisons of cell lysate and brain
homogenate M1000 infectivity, cell lysates were pre-
pared by harvesting and lysing in sterile phosphate buf-
fered saline (PBS; Invitrogen, Mulgrave, VIC, AUS) by
three cycles of freezing (10 minutes at -80°C) and thaw-
ing (3 minutes at 37°C), and centrifugation at 1000 × g
for 3 minutes at 4°C to obtain a post-nuclear superna-
tant. The total protein content of the PBS supernatant
and M1000 brain homogenate were determined by BCA
assay, and the lysates and homogenate were balanced to
the same protein concentration with PBS. Following this
100 μl of lysate or homogenate was mixed with 400 μl
of complete medium and this was used to infect recipi-
ent cells. For fraction infections 100 μl fraction (’neat’)
or, where indicated, fraction which had been serially
diluted in medium, was mixed with 400 μlc o m p l e t e
medium, and used to infect recipient MoRK13 cells. For
‘spiking’ experiments, M1000 brain homogenate was
diluted in 400 μl media and mixed with 100 μl MoRK13
or vecRK13 fraction (or as a control the lysis buffer
used to prepare cells prior to fractionation) to give a
final concentration of 0.05%, 0.025% and 0.0125%
M1000, prior to being used to infect recipient MoRK13
cells.
Subcellular fraction pre-treatments
For PK digestion, 100 μl of a fraction was treated with a
final concentration of 1 μg/ml PK for 8 hours at 37°C,
conditions found to reduce PrP
C by approximately 80%
when tested on control fractions (data not shown). For
sonication pre-treatment, 100 μlo faf r a c t i o ni na1 . 5m l
microfuge tube was subjected to 60 seconds at amplitude
70 in a S4000 sonicator (Misonix, Farmingdale, NY, USA)
with microplate horn adapter in 300 mL water maintained
at 37°C. The PK digested or sonicated fractions (and
untreated controls) were mixed with 400 μlo fc o m p l e t e
medium and used for in vitro infections as described
above.
Immunoblotting
For determination of subcellular localisation of PrP and
other proteins, fractions were mixed with 4X sample buf-
fer and subject to PAGE (using either 4-20% or 10-20%
Tris-glycine SDS or 4-12% Bis-tris NuPAGE pre-cast gels
(Invitrogen), depending on the size of the proteins to be
detected, and then transferred to PVDF membrane for
western blotting of PrP as described previously [79] and
organelle marker proteins using antibody dilutions as out-
lined in the manufacturer’s instructions (BD Pharmin-
gen™ Organelle Sampler Kit, BD Biosciences, North Ryde,
NSW, AUS). For detection of the ganglioside GM1 (lipid
raft marker), 3 μl of each fraction was spotted onto nitro-
cellulose membrane, and allowed to dry for 20 minutes at
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hour in 5% skim milk powder in PBS containing 0.05% (v/
v) Tween-20 (PBST) and then incubated in 1:100,000 cho-
lera toxin B subunit (CTB)-horseradish peroxidise (HRP)
conjugate (Sigma, stock concentration 0.45 mg/ml CTB
and 1 mg/ml HRP in H2O) solution in block for 1.5 hours
at room temperature prior to chemiluminescent detection
(ECL Plus, GE Healthcare, Rydalmere, NSW, AUS). For
PrP
res detection, fractions, cell lysates or brain homogenate
were digested with a final concentration of 50 μg/ml PK,
1h o u ra t3 7 ° Cb e f o r eS D S - P A G Ea n dw e s t e r nb l o t t i n g .
Dot blots of fractions were also carried out for PrP
res
detection, whereby 5 μl of fraction was spotted onto nitro-
cellulose membrane, which was dried 30-60 minutes at
37°C and then treated in exactly the same manner as the
cell blot assay nitrocellulose membrane. Cell blots for the
detection of PrP
res in recipient cells, at four passages (P4)
post-infection were carried out as described previously
[79]. All immunoblotting (western blots and cell blots) for
PrP species used the monoclonal antibody ICSM18, (D-
Gen, London, UK). All chemiluminescent images were
captured by a Fujifilm LAS-3000 (Berthold Australia,
Bundoora, VIC, AUS).
In vivo prion transmissions
All animal experiments were carried out in strict accor-
dance with the ‘Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes (NHMRC)’,
with approval from the University of Melbourne Animal
Ethics Committee (AEC #04154). Tga20 PrP
C over-
expressing mice [82] were anesthetised using methoxy-
fluorane and inoculated intracerebrally with 30 μlo f
0.01% M1000 brain homogenate diluted in PBS or the
appropriate fractions as indicated, or with 30 μlo f‘neat’
fraction or whole cell PBS lysate. Mice were provided
food and water ad libitum and housed following routine
animal husbandry practices. Mice were examined daily
for symptoms of prion disease. Once mice developed per-
sisting features of advanced prion disease, including
impaired righting reflexes, hunched posture and hind
limb paresis, they were culled by cervical dislocation
under anaesthesia and the number of days post-inocula-
tion was recorded. Brains were removed and sagittally
hemi-sectioned, with half the brain fixed and stained to
allow scoring of vacuolation, astrocytic gliosis and PrP
deposition as described previously [40], and the other
half made to 10% (w/v) homogenates in PBS, with homo-
genates stored at -80°C until required. Neuropathological
scoring was performed on two separate occasions,
blinded as to the inoculum group, to provide a semi-
quantitative comparison of lesion profiles between the
groups of animals. Stained sections were visualised using
a Zeiss Axioskop 50 microscope with images captured
using a Zeiss AxioCam HRC camera (Carl Zeiss, North
Ryde, NSW, AUS).
Densitometry and statistical analysis
All densitometric analyses used the public domain ImageJ
software (National Institutes of Health, USA). For deter-
mining relative levels of PrP
res in fractions, each fraction
PrP
res dot blot signal intensity was measured, with the
sum of the 10 individual PrP
res levels providing the ‘total
PrP
res’; each individual fraction was expressed as a percen-
tage of the total PrP
res. For determining relative levels of
infectivity contained within MoRK13-infectious fractions,
PrP
res produced by MoRK13 cells exposed to each ‘neat’
fraction was measured at passage 4 (P4) post-exposure by
cell blot signal intensity, with the sum of the 10 individual
PrP
res levels providing ‘total PrP
res’. Once again, each indi-
vidual fraction was expressed as a percentage of the calcu-
lated total PrP
res. All statistical analyses were performed in
GraphPad Prism 4, with one way ANOVA and Tukey’s
multiple comparisons or two way ANOVA and Bonfer-
onni post-tests used as indicated, unless stated otherwise.
Additional material
Additional file 1: Figure S1. Disparity in PrP
res levels and relative
infectivity in the MoRK13-inf cell prion infection model. Representative
western blot (A) and quantification (B) of PrP
res levels in MoRK13-inf
whole cell lysates relative to M1000 brain homogenate (n = 3). Samples
were balanced for total protein; 5 μg total protein was resolved in
untreated (-) lanes; 50 μg total protein was proteinase K (PK) digested (+)
and resolved on 4-12% Bis-tris NuPAGE gels. Very long exposures were
required to visualise the PrP
res within cell lysates, hence the loss of
distinction between M1000 PrP
res glycoforms. Representative cell blot (C)
and quantification (D) of PrP
res produced by recipient MoRK13 cells
infected with equivalent total protein amounts of M1000 or MoRK13-inf
cell lysate (n = 3). Note infections utilised the corresponding lysate/
homogenate shown in (A). NBH = Balb/c normal brain homogenate.
Statistical analysis by one way ANOVA; *** p < 0.001, ** p < 0.01.
Additional file 2: Figure S2. Localisation of PrP, organelle and membrane
markers in Nycodenz density gradient fractions of alternative cell lines.
Representative immunoblots of subcellular fractions obtained from vector
only transfected RK13 cells (vecRK13), GT1-7H and (M1000 infected) GT1-7H-
inf, subject to SDS-PAGE and western blotting as described in the methods.
CTB dot blot - 3 μl of fraction was dried onto nitrocellulose membrane, and
blotted as described in the methods. LR = lipid raft; ER = endoplasmic
reticulum; MT = mitochondria; EE = early endosome; CTB = cholera toxin
subunit B; Flot1 = Flotillin 1; Bcl-2 = anti-apoptotic MT marker protein; Bip =
ER lumen chaperone protein; EEA1 = EE antigen 1.
Additional file 3: Figure S3. Localisation of PrP isoforms, organelle and
membrane markers in Nycodenz density gradient fractions of M1000
brain. Representative immunoblots of subcellular fractions obtained from
terminal M1000 brain. Brains were homogenised in a comparative way to
the detergent-free cell lysis described in the methods, and then subject
to Nycodenz gradient fractionation. Briefly, whole brains (snap frozen in
liquid N2 and stored at -80°C) were homogenised in TNE buffer by
passing the tissue through an 18 g and then a 20 g needle until an even
homogenate was formed, followed by exactly 20 passes through a 22 g
needle. The homogenate was centrifuged at 1000 × g, 10 minutes at 4°
C, the post-nuclear supernatant was retained on ice and the extraction
repeated on the pellet. The supernatant was then subject to Nycodenz
gradient floatation, fractions were collected and analysed by SDS-PAGE
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res and CTB dot blots - 3 μlo f
fraction was dried onto nitrocellulose membrane, and blotted as
described in the methods. CTB = cholera toxin subunit B; Flot1 = Flotillin
1; Bcl-2 = anti-apoptotic mitochondrial marker protein; Bip = ER lumen
chaperone protein.
Additional file 4: Figure S4. Illustration of the reduction of infectious
titre in a 35-day extension of incubation period in Tga20 mice.
Regression analysis (modelled on the results of an incubation time
interval assay based on quantal end-point dose titration of M1000 brain
homogenate in Tga20 mice) was used to plot the relationship between
incubation period and titre (V.A. Lawson, unpublished data). The red and
blue lines highlight an incubation period of 35 days and the
corresponding titres.
Additional file 5: Figure S5. Assessment of neuropathology in the
brains of Tga20 mice inoculated with 0.01% (w/v) M1000 brain
homogenate, MoRK13 and MoRK13-inf whole cell lysates and selected
MoRK13-inf fractions. Representative photomicrographs demonstrating
the degree of (A) vacuolation in hematoxylin and eosin-stained (H & E)
sections, (B) astrocytic gliosis in glial fibrillary acidic protein (GFAP)
stained sections, and (C) PrP plaque deposition in ICSM18 stained
sections of various brain regions as indicated. Magnification = 50 × for all
sections/stains except H & E stained hippocampus and occipital pole,
where magnification = 100 ×.
Additional file 6: Figure S6. PrP
res profiles in Tga20 mice inoculated
with 0.01% (w/v) M1000 brain homogenate, MoRK13-inf and selected
MoRK13-inf subcellular fractions. Representative western blot (A) and
quantification (B) of PrP
res glycoform ratios in terminal mice brains after
intracerebral inoculation as indicated. (A) 10 μl of PK digested (100 μg/ml
final concentration PK, 1 hour at 37°C) 10% (w/v in PBS) homogenate
was resolved on 12% Bis-tris NuPAGE and probed with ICSM18 primary
antibody and (B) quantified using ImageJ. Di = di-glycosylated PrP
res,
mono = mono-glycosylated PrP
res, un = unglycosylated PrP
res. Statistical
analysis by two-way ANOVA with Bonferroni post-tests; ns = no
significant differences;
#M1000 in Balb/c mice was significantly different
to all other inocula; ^0.01% M1000 in Tga20 mice was significantly
different to all other inocula.
Additional file 7: Figure S7. Exogenous cellular co-factors from vecRK13
do not differentially increase the efficiency of M1000 infection in vitro. (A)
Cell blot showing PrP
res levels produced by recipient MoRK13 cells
exposed to M1000 brain homogenate diluted to three different final
concentrations (as indicated) with either 1:4 lysis buffer (LB):medium or
1:4 vecRK13 fraction:medium mix. (B) Quantification of PrP
res produced
by MoRK13 cells exposed to M1000 brain homogenate diluted in
subcellular fraction relative to the equivalent % M1000 brain
homogenate diluted in lysis buffer; for quantification purposes the three
different % M1000 spikes into the same vecRK13 fractionated lysate were
considered a triplicate of the same experiment, with the error bars
representing this intra-experiment variation, and analysis of this variation
(one way ANOVA) showing no significant differences. Fractions enriched
in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial (MT) and early
endosome (EE) marker proteins are as marked.
Additional file 8: Figure S8. Lesion profiles from Tga20 mice
intracerebrally inoculated with M1000 brain homogenate diluted in PBS
and high density Nyocodenz with or without MoRK13 cell lysate content.
Lesion profiles generated by quantification of the degree of vacuolation
(H&E), reactive astrocytosis (GFAP) and PrP plaque deposition in each
brain region (HI - hippocampus, TH - thalamus, OP - occipital pole, CE -
cerebellum, MB - midbrain, PO - pons). n = 3 or 4 for all brain regions
except in 0.01% M1000 diluted in PBS HI PrP plaque deposition, where n
= 2. Statistical analysis comparing lesion profiles was by two way ANOVA.
For astrocytic gliosis and PrP plaque deposition, *p < 0.05 comparing
M1000 diluted in PBS and Nycodenz fraction #10 in TH region only. No
other significant differences seen.
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